BMS-986189

BMS-986189 is a macrocyclic peptide PD-1/PD-L1 interaction with an IC50 of 1.03 nM inhibitor. BMS-986189 can be used for cancer research, such as human lung carcinoma cells L2987[1][2].

Product Specifications

CAS Number

1629665-96-8

UNSPSC

12352209

Target

PD-1/PD-L1

Type

Peptides

Related Pathways

Immunology/Inflammation

Applications

COVID-19-immunoregulation

Field of Research

Cancer; Inflammation/Immunology

Assay Protocol

https://www.medchemexpress.com/bms-986189.html

Purity

99.58

Solubility

DMSO : ≥ 100 mg/mL|H2O : ≥ 1 mg/mL

Smiles

OC(CN1C2=CC=CC=C2C(C[C@H]3C(N([C@H](C(N([C@H](C(N[C@H](C(N[C@@H](CSCC(N[C@H](C(N([C@H](C(N[C@H](C(N4[C@](CCC4)([H])C(N[C@H](C(N[C@H](C(N5[C@](C[C@H](C5)O)([H])C(N[C@H](C(N[C@H](C(N3)=O)CCN)=O)CC6=CNC7=CC=CC=C67)=O)=O)CC(C)C)=O)CN)=O)=O)CC(N)=O)=O)C)C)=O)CC8=CC=C(C=C8)O)=O)C(NCC(N)=O)=O)=O)CC(C)C)=O)CCCC)C)=O)CCCC)C)=O)=C1)=O

Molecular Formula

C91H131N21O21S

Molecular Weight

1887.21

References & Citations

[1]Yang J, et al. Utilization of macrocyclic peptides to target protein-protein interactions in cancer. Front Oncol. 2022 Nov 17;12:992171.|[2]Donnelly DJ, et al. The discovery and evaluation of [18F]BMS-986229, a novel macrocyclic peptide PET radioligand for the measurement of PD-L1 expression and in-vivo PD-L1 target engagement. Eur J Nucl Med Mol Imaging. 2024 Mar;51 (4) :978-990.